A Study of Vonoprazan in Adults With Helicobacter Pylori
Condition: Helicobacter Pylori
Intervention: Clarithromycin; Amoxicillin; Bismuth potassium citrate; Esomeprazole; Vonoprazan
Intervention description: Clarithromycin tablets.; Amoxicillin capsules.; Bismuth potassium citrate tablets.; Esomeprazole tablets.; Vonoprazan tablets.
Intervention MeSH terms: Amoxicillin; Clarithromycin; Potassium Citrate; Esomeprazole; Bismuth
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Enrollment: 44.0
Sex: All
Minimum age: 18 Years
Maximum age: 60 Years
Healthy volunteers: No
Keywords: Drug Therapy

Summary:

      Helicobacter Pylori (H Pylori) is a bug found in the digestive system. It can cause soreness
      and redness in the stomach (gastritis). It can also cause ulcers in the stomach and other
      parts of the digestive system. Vonoprazan is a medicine to treat people with H Pylori. It is
      taken together with other medicines to fight infections caused by H Pylori.

      The main aim of this study is to learn if vonoprazan changes how the other medicines are
      processed by the body. It will be compared with another medicine called esomeprazole. Other
      aims are to check for side effects from the study medicines.

      At the first visit, the study doctor will check who can take part. Participants who take part
      will be picked for 1 of 2 treatments by chance.

        -  Vonoprazan taken with bismuth, clarithromycin, and amoxicillin

        -  Esomeprazole taken with bismuth, clarithromycin, and amoxicillin

      Both treatments will last for 14 days. Participants will stay in the clinic throughout their
      treatment.

      After treatment, the clinic staff will telephone the participants 2 days later for a
      check-up. The participants will visit the clinic 4 weeks later for a final check-up.
    

Eligibility criteria:

        Inclusion Criteria:

          1. HP positive participants.

          2. Weighs at least 50 kilogram (kg) and has a body mass index between greater than (>) 18
             and less than equal to (<=) 30 kilogram per square meter (kg/m^2), inclusive, at
             screening and Day -1 (check-in).

          3. Is willing to abstain from strenuous exercise from 72 hours before first dose (Day 1)
             until the Follow-up call on Day 17.

        Exclusion Criteria:

          1. Has a positive urine drug result for drugs of abuse at Screening or Check-in (Day -1).

          2. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse (defined as regular consumption of 21 units or more units per week) at any time
             prior to the Screening Visit or is unwilling to agree to abstain from alcohol and
             drugs throughout the study (up to Day 17).

          3. Has history of gastroesophageal reflux disease (GERD), symptomatic GERD, erosive
             esophagitis, duodenal ulcer, gastric ulcer, Barrett's esophagus, or Zollinger-Ellison
             syndrome, or has current or recent (within 6 months) gastrointestinal disease that
             would be expected to influence the absorption of drugs.

          4. Has undergone therapeutic upper gastrointestinal endoscopic therapy (example,
             endoscopic hemostasis or excision including biopsy) within 30 days prior to Screening.

          5. Has undergone major surgical procedures within the past 1 month or are scheduled to
             undergo surgical procedures that may affect gastric acid secretion (example, abdominal
             surgery, vagotomy, or craniotomy).

          6. Has a history of cancer, except basal cell carcinoma or Stage 1 squamous cell
             carcinoma of the skin that has been in remission for at least 5 years prior to Day 1.

          7. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen at Screening.

          8. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 6 weeks prior to
             Check-in. Cotinine test is positive at Screening or Check-in.

          9. Has poor peripheral venous access.

         10. Has donated or lost 450 milliliter (mL) or more of his blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 90 days prior to Day
             1.

         11. Has abnormal Screening or Check-in laboratory values that suggest a clinically
             significant underlying disease or subject with the following laboratory abnormalities:
             alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin >
             the upper limit of normal (ULN).

         12. Has reduced renal function assessed by having an estimated glomerular filtration rate
             <90 milliliter per min per 1.73 square meter (mL/min/1.73 m^2) (as estimated by
             Chronic Kidney Disease-Epidemology Collaboration) at Screening or Check-in.